Psychiatry Archives -

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide

Newron says pivotal treatment-resistant schizophrenia trial is a go

https://pharmaphorum.com/news/newron-says-pivotal-treatment-resistant-schizophrenia-trial-is-a-go/

Market Access/ News/ News/ News/ Sales and Marketing

AbbVie claims key approval for Vraylar in depression

Phil Taylor AbbVie, depression, Psychiatry, regulatory approval, Vraylar 0 Comment

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to

AbbVie claims key approval for Vraylar in depression

https://pharmaphorum.com/news/abbvie-claims-key-approval-for-vraylar-in-depression/

News/ News/ News/ R&D/ Sales and Marketing

J&J builds case for antidepressant Spravato with head-to-head trial

Phil Taylor depression, Janssen, Johnson & Johnson, Psychiatry, Spravato 0 Comment

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in

J&J builds case for antidepressant Spravato with head-to-head trial

https://pharmaphorum.com/news/jj-builds-case-for-antidepressant-spravato-with-head-to-head-trial/

News/ News/ R&D

Largest-ever trial backs psilocybin treatment for depression

Phil Taylor Compass Pathways, depression, psilocybin, psychedelics, Psychiatry 0 Comment

The psychedelic compound in magic mushrooms – psilocybin – can improve the symptoms of severe depression, according to

Largest-ever trial backs psilocybin treatment for depression

https://pharmaphorum.com/news/largest-ever-trial-backs-psilocybin-treatment-for-depression/

jason-rosewell-voice-microphone-child-unsplash

Digital/ News/ News/ News/ R&D

Could cancer be diagnosed from the sound of a voice?

Phil Taylor cancer, diagnostic, digital, digital health, neurology, Owkin, Psychiatry, vocal biomarkers 0 Comment

A $14 million research project is getting underway in the US to see whether cancer and other diseases

Could cancer be diagnosed from the sound of a voice?

https://pharmaphorum.com/news/could-cancer-be-diagnosed-from-the-sound-of-a-voice/

Market Access/ News/ News

Axsome bounces back as FDA clears depression drug

Phil Taylor Auvelity, Axsome Therapeutics, depression, Johnson & Johnson, Psychiatry, regulatory approval, Spravato 0 Comment

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a

Axsome bounces back as FDA clears depression drug

https://pharmaphorum.com/news/axsome-bounces-back-as-fda-clears-depression-drug/

Digital/ Market Access/ News/ News/ News

NICE backs AliveCor’s smartphone-linked ECG for NHS use

Phil Taylor AliveCor, diagnostics, digital, digital health, ECG, NHS, NICE, Psychiatry 0 Comment

In draft guidance, NICE has said that AliveCor’s ECG recording device should be an option to check or

NICE backs AliveCor’s smartphone-linked ECG for NHS use

https://pharmaphorum.com/news/nice-backs-alivecors-smartphone-linked-ecg-for-nhs-use/

News/ News/ R&D

Sosei Heptares banks $30m milestone in Neurocrine Bio alliance

Phil Taylor Karuna Therapeutics, Neurocrine Biosciences, partnering, Psychiatry, schizophrenia, Sosei Heptares 0 Comment

Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage clinical trials, earning

Sosei Heptares banks $30m milestone in Neurocrine Bio alliance

https://pharmaphorum.com/news/sosei-heptares-banks-30m-milestone-in-neurocrine-bio-alliance/

News/ News/ R&D

VistaGen’s horizons may shrink after clinical trial setback

Phil Taylor central nervous system, Psychiatry, social anxiety disorder, VistaGen Therapeutics 0 Comment

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed

VistaGen’s horizons may shrink after clinical trial setback

https://pharmaphorum.com/news/vistagens-horizons-may-shrink-after-clinical-trial-setback/

Trending

Psychiatry

Login